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Abstract
Anergy, a condition in which cells persist in the periphery but are unresponsive to antigen, is
responsible for silencing many self-reactive B cells. Loss of anergy is known to contribute to the
development of autoimmune diseases, including systemic lupus erythematosus and type 1
diabetes. Multiple transgenic mouse models have enabled the dissection of mechanisms that
underlie anergy, and recently, anergic B cells have been identified in the periphery of wild-type
mice. Heterogeneity of mechanistic concepts developed using model systems has complicated our
understanding of anergy and its biological features. In this Review, we compare and contrast the
salient features of anergic B cells with a view to developing unifying mechanistic hypotheses that
explain their lifestyles.
The generation of B cells occurs throughout life and proceeds through several distinct stages
and checkpoints (FIG. 1). After birth, B-cell generation occurs in the bone marrow, where
cells progress through pro-B-cell and pre-B-cell stages of development. At the next stage (as
immature B cells), they acquire antigen specificity by virtue of expression of a functional B-
cell receptor (BCR); this is also the first key specificity checkpoint in B-cell development.
Cells that successfully traverse this phase enter the periphery as transitional B cells.
The ability of the adaptive immune system to provide protection against pathogens requires
a diverse BCR repertoire that can recognize a broad range of foreign proteins. Diversity is
generated early in development by random rearrangement of immunoglobulin genes. This
inevitably results in the genesis of receptors that recognize self antigens. It is estimated that
75% of human early immature B cells are self-reactive1. About a third of these self-reactive
immature B cells are purged from the repertoire by receptor editing, wherein renewed
immunoglobulin gene rearrangement generates a new light chain to pair with the existing
immunoglobulin heavy chain in an anthropomorphic effort to generate a non-self-reactive
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BCR2,3. Failing this, these B cells are deleted by apoptosis4. Despite these mechanisms of
central tolerance, many self-reactive B cells escape to the periphery where they are silenced
by an induced state of unresponsiveness known as anergy (BOX 1). Anergy can be viewed
as nothing more than the state of lethargy that ensues when B cells mount a normal initial
response to antigen but fail to receive secondary signals that sustain their activation.
Paradoxically, the maintenance of anergy requires chronic binding of antigen and signal
transduction, yet the stimulation of unoccupied receptors fails to trigger signal transduction
pathways that are required for B-cell activation and/or differentiation.
Anergic B cells have several features that distinguish them from naive B cells. However,
these features vary among models of B-cell anergy. The features include, but are not limited
to, reduced lifespan, altered migration and anatomical localization, and an inability to
interact productively with helper T cells. These mechanisms act in concert to limit the ability
of anergic cells to participate in immune responses. Classically, B-cell anergy has been
studied using transgenic mouse models in which antigen specificity is fixed. Many features
of anergic cells observed in transgenic models are shared by a recently defined population of
naturally occurring anergic B cells, known as An1 B cells. In this Review, we compare
mouse models of B-cell anergy in an effort to define unifying concepts that explain how
anergy is maintained. The first section introduces the models, defines the antigen specificity
of each and briefly describes the attributes of the various systems. The second section
focuses on the biochemical and phenotypic characteristics of B cells in each model. The
salient features of each model are summarized in TABLE 1.
Immunoglobulin-transgenic anergy models
The hen-egg-lyzozyme-specific model
The most widely studied transgenic model of B-cell anergy uses hen-egg lysozyme
(HEL)5–8 as a neo-self antigen. To construct this model (designated MD4 × ML5), MD4
mice were engineered to co-express transgenes encoding immuno globulin heavy chains
(both µ and δ heavy chains) and light chains to produce a BCR with high affinity for HEL
(approximately 2 × 10−9 M)6. These mice were bred with a second transgenic strain that
expresses soluble HEL, referred to as ML5 mice. Although most B cells from MD4 × ML5
mice express a BCR that recognizes HEL, B-cell development proceeds relatively normally
as indicated by the presence of transitional 1 (T1), T2, T3 and follicular B-cell subsets in the
periphery. However, the absolute number of mature follicular B cells is substantially less
than that observed in MD4 mice and a strong skewing towards the T3 B-cell stage is
evident. Importantly, chronic exposure of the peripheral B cells in these mice to HEL (serum
levels greater than 10–20 ng per ml) results in anergy. As a consequence, these mice fail to
mount adaptive responses (as determined by serum antibody titres) following immunization
with exogenous HEL6, and they exhibit a reduced capacity to generate antibody-secreting
cells in response to the Toll-like receptor (TLR) agonists CpG-containing DNA and
lipopolysaccharide (LPS)9,10.
The DNA-specific models
The presence of serum antibodies specific for DNA is a defining feature in the autoimmune
disease systemic lupus erythematosus (SLE), as well as in mouse models of this disease,
such as MRL.Faslpr/lpr mice. Immunoglobulin-transgenic mice (transgenic for the µ heavy
chain only) were generated to express a DNA-specific immunoglobulin-heavy-chain
variable region (3H9) derived from a MRL.Faslpr/lpr mouse with disease11; the transgenic
heavy chain pairs with endogenous light chains generating mice designated VH3H9.
Therefore, VH3H9 mice have a polyclonal B-cell repertoire enriched for B cells specific for
single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA), in addition to a
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population of non-DNA-specific B cells12. VH3H9 mice (on a BALB/c background)
produce normal numbers of IgM+ B cells in the periphery yet do not contain DNA-specific
serum antibodies, indicating that the DNA-specific B cells in these mice are anergic12.
Similarly, when the VH3H9 heavy chain is forced to pair with the ssDNA-specific light
chain (Vκ8) in double-transgenic mice (VH3H9 × Vκ8 mice), normal numbers of IgM+ B
cells are found in the periphery13 but no ssDNA-specific antibodies are detected in the
serum14. The anergic phenotype of B cells from the VH3H9 mice is breached when these
mice are crossed with the autoimmune-prone MRL.Faslpr/lpr mice, as demonstrated by the
presence of DNA-specific antibodies in the serum of 10-week-old VH3H9 × MRL.Fasllpr/lpr
mice15. It should be noted that the levels of serum DNA-specific antibody in these mice
mirror those of non-transgenic MRL. Faslpr/lpr mice15. In a third DNA-specific model of
anergy, pairing of the VH3H9 heavy chain with a transgenic Vλ2 light chain produces
dsDNA-specific B cells. In these VH3H9 × Vλ2 mice, IgM+ B cells are present in the
periphery (albeit in reduced numbers) but no serum dsDNA-specific antibodies are
detectable, again consistent with the efficient induction of anergy of the autoreactive B
cells13.
The Smith-antigen-specific model
Smith antigen (Sm)-specific B cells are dysregulated in 25–30% of patients with SLE16. Sm,
a component of the small nuclear ribonucleoprotein (snRNP) complex involved in pre-
mRNA splicing, can activate B cells through the BCR and TLR7 (REF. 17). To define how
tolerance to this proteinaceous nuclear self antigen is maintained, Sm-specific
immunoglobulin-transgenic mice (with a µ heavy chain only) were developed. These mice
express a heavy chain (VH2–12) identified in B cells from MRL.Faslpr/lpr mice with
disease18. The VH2–12 pairs with endogenous light chains to produce a B-cell repertoire in
which most cells are Sm specific, but vary in affinity19,20. Transitional (T1 and T2) and
follicular B-cell subsets are found at normal frequencies, however VH2–12 mice exhibit a
twofold increase in marginal-zone B cells and early pre-plasma cells19–21. Although VH2–
12 mice do not spontaneously secrete Sm-specific antibody, immunization with snRNPs
induces a Sm-specific response, indicating that a subset of B cells fails to be tolerized or that
immunization overcomes tolerance22. Similar to the DNA-specific model, VH2–12 mice
crossed with autoimmune-prone MRL.Faslpr/lpr or B6.Faslpr/lpr mice spontaneously produce
Sm-specific antibody by 8 weeks of age19,21. This shows that although effectively silenced
on a non-autoimmune background, tolerance is lost on an autoimmune-prone background.
To study how low-affinity Sm-reactive B cells are tolerized, a model was generated wherein
the light chain of VH2–12 mice was restricted to Vκ8. This heavy–light chain pairing was
identified in MRL.Faslpr/lpr mice and proposed to bind Sm with low affinity23,24. The VH2–
12 × Vκ8 mice have normal frequencies of follicular, T1 and T2 B cells but are deficient in
marginal-zone B cells24. The B cells from VH2–12 × Vκ8 mice neither spontaneously
secrete immunoglobulin24 nor produce Sm-specific antibody on immunization with snRNPs
(M.A. Kilmon and B.J.V., unpublished observations). This suggests that the low affinity
(Vκ8-expressing) B cells in VH2–12 × Vκ8 mice are not responsible for the loss of tolerance
seen when the concentration of snRNPs is increased. Furthermore, these data suggest that
unique mechanisms may be responsible for anergic silencing of B cells that express BCRs of
different affinities for antigen. Alternatively, the binding avidity of snRNPs may simply be
too low to activate B cells bearing these low affinity receptors.
The insulin-specific model
Another model of B-cell anergy was developed to study tolerance to insulin. In this model,
transgenes encoding the µ heavy- and light-chain V-region genes from the insulin-specific
125 B-cell hybridoma (generated during a primary immune response in BALB/c mice to
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human insulin, with an affinity of 1 × 10−7 M for rodent insulin25) were introduced into
C57BL/6 mice26; these mice were crossed with diabetes-prone NOD (non-obese diabetic)
mice. On both C57BL/6 and NOD backgrounds, B cells from Vh125×Vκ125 mice (also
known as 125Tg mice) develop normally to become follicular and marginal-zone B cells27.
However, these mice fail to spontaneously secrete insulin-specific antibodies and fail to
generate insulin-specific antibodies on immunization with bovine or porcine insulin26.
Despite the apparent anergic phenotype of the insulin-specific B cells, VH125 ×
Vκ125.NOD mice develop diabetes at a similar rate to non-transgenic NOD mice27. This
suggests that in this system chronic exposure to insulin causes a less stringent form of
anergy. The reason for this is unclear, but it may be due to the affinity of the transgenic BCR
for insulin, the availability of sufficient insulin or the avidity of available insulin.
The arsonate-specific model
B cells from the azophenyl-arsonate (Ars)-specific model (also known as the Ars/A1 model)
express surface immunoglobulin (IgM and IgD) that has moderate affinity (2.5 × 10−5 M)
for the Ars hapten28. In this model, Ars-specific B cells progress through T1, T2 and T3 B-
cell stages, however, follicular and marginal-zone B cells are poorly represented29. The
peripheral populations are greatly enriched in T3 cells. Importantly, the Ars-specific BCR
crossreacts with 100 times lower affinity to ssDNA, resulting in anergy, as indicated by the
unresponsiveness of these mice to Ars-containing immunogens. The Ars-specific system, by
virtue of receptor crossreactivity with self, provides an excellent model of pathogen mimicry
of self antigen. In addition, high-affinity hapten reactivity has been invaluable in allowing
analysis of the reversibility of anergy. Competition studies showed that the anergic state of
Ars-specific B cells can be reversed in vitro by culture in the presence of a monovalent
hapten (Ars-tyrosine) of higher affinity than the self antigen for the BCR30. Upon recovery
from the anergic state (which occurs within seconds), some defects in signal transduction are
lost and cells become responsive to Ars-containing immunogens. These results indicate that
anergy is not maintained by a mechanism such as genetic reprogramming. The ability to
reverse anergy was also demonstrated using the MD4 × ML5 system. In this model, anergic
B cells remained unresponsive for ~48 hours following transfer of the cells to an antigen-
free animal5. This delay may reflect the inability to displace high-affinity antigen from the
BCR.
Naturally occurring anergic B cells
Although the use of BCR-transgenic models has contributed seminally to our understanding
of B-cell anergy, the issue of whether such models accurately reflect naturally occurring
tolerance mechanisms has always been a concern. Perhaps more fundamental was the
question of the physiological importance of anergy in silencing self-reactive B cells. These
issues were largely addressed by the recent identification of naturally occurring anergic B
cells in the periphery of non-autoimmune C57BL/6 mice29. By comparing the expression of
a range of cell-surface markers on anergic B cells from different BCR-transgenic models, it
was shown that both the Ars- and the HEL-specific mouse models are characterized by the
development of a subset of B cells with a cell-surface phenotype that corresponds to that
previously reported for T3 B cells (FIG. 1). T3 B cells from C57BL/6 mice were found to be
enriched in self-reactive cells (compared with other B-cell subsets) and exhibited other
markers of anergy, including attenuated BCR-mediated signalling. Importantly, BCR-
transgenic mice expressing only non-autoreactive B cells, such as MD4 mice, do not contain
T3 B cells. Finally, mature MD4 B cells rapidly adopt the T3 B-cell phenotype upon transfer
to ML5 mice. It is therefore apparent that the T3 B-cell stage is perhaps not strictly
transitional, and these cells have been designated An1 B cells. Although the An1 B-cell
population is predominant in Ars- and HEL-specific models, it is negligible in the Sm- or
insulin-specific models, suggesting that An1 B cells may reflect only one of multiple anergic
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phenotypes found in the periphery. Nevertheless, the existence of An1 B cells in a
physiological repertoire demonstrates that anergy is biologically important. Finally, these
studies confirm the fidelity of transgenic mice as models of physiological B-cell anergy.
Importantly, the short lifespan of physiological An1 B cells (~5 days)83, relative to most
peripheral B cells (~40 days), considered in the context of An1 B-cell frequency (~6–8%),
suggests that in normal animals ~50% of newly formed B cells are destined to become
anergic. Finally, recent work has shown that the T3 B-cell population is reduced in
lupusprone mouse models addressing a possible pathogenic role for these self-reactive B
cells in autoimmunity31.
Characteristics of anergic B cells
In the following section, we review the phenotypic characteristics of anergic B cells from
the extant models. In particular, we highlight the heterogeneity among models and suggest
potential underlying bases for these variations.
Developmental ‘arrest’
The differentiation of mature B cells into plasma cells (FIG. 1) is required for the high level
of secretion of antibody seen in an immune response. Logically, preventing self-reactive B
cells from differentiating should limit the generation of pathogenic autoantibodies.
Accordingly, reports have identified several stages of B-cell development at which B cells
expressing a self-reactive BCR are arrested. As mentioned, in MD4 × ML5 and Ars-specific
mice, a significant proportion of peripheral B cells would appear (see earlier) to be arrested
at the T3 B-cell stage, exhibiting a surface phenotype identical to that of An1 B cells in
wild-type mice. Similarly, dsDNA-specific B cells from VH3H9 and VH3H9 × Vλ2 mice
show such a developmental defect. These B cells arrest at an immature and/or transitional
stage, again limiting the number of cells entering the mature B-cell population13,32. The
importance of this checkpoint for maintaining tolerance is clearly highlighted by the breach
in this developmental block that occurs in autoimmune-prone MRL.Faslpr/lpr VH3H9/Vλ2
mice, in which B-cell progression to full maturity parallels disease development15. Sm-
specific splenic B cells from VH2–12 mice arrest at a later stage in development, as early
pre-plasma cells (CD19+CD138mid)21. Interestingly, ssDNA- and Sm-specific splenic B
cells (from VH3H9 × Vκ8 mice and VH2–12 × Vκ8 mice, respectively) do not exhibit a
block in development and have mature follicular B cells that populate the spleen33.
It is unclear why autoreactive B cells arrest at different stages of development. It seems
likely that the B cells with low affinity and/or avidity for self antigen, such as in VH125 ×
Vκ125, VH3H9 × Vκ8 and VH2–12 mice, may be deemed to be of less risk to the host and
allowed to proceed through development. Regardless, given the variation among anergy
models in B-cell development, it is clear that mechanisms other than developmental
regulation must ensure that these cells don’t run riot.
Decreased lifespan
It is widely accepted that anergic B cells have a half-life that is considerably shorter than
non-self-reactive mature B cells in vivo (1–5 days as opposed to 40 days34,35). A reduced
lifespan is thought to purge the repertoire of potentially harmful B cells. However, in early
studies using MD4 × ML5 animals, the survival of anergic HEL-specific B cells was shown
to be indistinguishable in vivo from that of non-self-reactive B cells, suggesting that anergic
B cells have no intrinsic survival defects36. Subsequently it was shown that, when
competing with non-anergic B cells, the half-life of anergic B cells is substantially
decreased36,37. It was years before the underlying basis of this phenomenon was defined.
The discovery of B-cell-activating factor (BAFF; also known as BLYS) as a major survival
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factor for peripheral B cells was key to resolving this issue38. It was shown that anergic B
cells compete poorly with non-anergic B cells for limited ambient BAFF39. The signal
provided by BAFF is thought to be required to override the high levels of pro-apoptotic
proteins, such as BIM (BCL-2-interacting mediator of cell death), that are present in anergic
cells owing to chronic self-antigen-induced signalling through the BCR. Indeed, the deletion
of Bim in MD4 × ML5 mice has been shown to result in the production of HEL-specific
antibodies40.
The shortened half-life of anergic B cells has also been recognized in other models.
Bromodeoxyuridine (BrdU)-incorporation experiments have confirmed increased turnover
rates in ssDNA- and dsDNA-specific models14,24,41, but not for anergic B cells from the
insulin- or Sm-specific models.
Although competition for BAFF is probably important, it is unlikely to be the sole cause of
the short half-life of anergic B cells. We have shown that the removal of self antigen in vitro
by competition with monovalent hapten can result in a substantial recovery of the half-life of
anergic cells, suggesting that chronic BCR signalling is required to initiate pro-apoptotic
pathways30. Alternatively, self-antigen-induced signalling may alter the BAFF response
through ‘receptor crosstalk’.
Another mechanism for the deletion of self-reactive B cells is FAS-mediated apoptosis
consequent to interaction with FAS ligand (FASL)-expressing CD4+ T cells. Several lines of
evidence suggest that this may be an important mechanism. First, mice deficient in either
FAS (MRL.Faslpr/lpr) or FASL (B6.Faslgld/gld) are prone to spontaneous autoimmunity with
age (reviewed in REF. 42). Second, the interaction of anergic HEL-specific B cells with
HEL-specific CD4+ T cells results in B-cell apoptosis and not a break in B-cell anergy43.
Last, overexpression of the co-stimulatory molecule CD86 has been shown to prevent FAS-
mediated deletion of B cells by HEL-specific CD4+ T cells and results in the production of
HEL-specific antibodies, indicating a break in anergy44. Notably, not all anergic B cells
express FAS, suggesting that FAS-mediated deletion in anergy is not a universal mechanism
of tolerance.
Paradoxically, in vivo studies also suggest that T cells (adoptively transferred allogeneic T
cells) are capable of breaking B-cell anergy in the HEL-specific model in which HEL is
present in its soluble form45. This is complemented by data showing that both cognate and
allogeneic T cells break anergy in DNA-specific models in vivo46,47. However, another
study reported an inability of allogeneic T cells to break anergy in the HEL-specific system,
unless HEL was provided as a membrane-bound form48. The ability of the membrane-bound
form of HEL to break B-cell anergy in the presence of allogeneic T cells might be related to
its higher avidity for the HEL-specific BCR and hence its ability to deliver a qualitatively
stronger signal to anergic B cells. Interestingly, anergic HEL-specific B cells exposed to
forms of HEL that efficiently crosslink the BCR have been shown to be resistant to FAS-
mediated apoptosis49. Together, these data set precedence for T-cell-mediated reversal of B-
cell anergy, and suggest that the level of BCR crosslinking by self antigen can determine
both the outcome of this response and the sensitivity to FAS-mediated apoptosis. One point
to be kept in mind when interpreting studies on the role of T-cell help in reversing B-cell
anergy is the availability of T-cell help relative to the timing of self-antigen-induced
signalling. Cook et al.50 have shown that T-cell-derived signalling must be available soon
after self-antigen-induced signals are delivered to the B cells to prevent the induction of
anergy.
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The localization of B cells in appropriate microenvironments of secondary lymphoid organs
is essential for the development of B-cell immunity. Specifically, localization to follicular
regions of the spleen is thought to allow effective sampling of protein antigens in an
environment that is rich in B-cell survival factors.
Early studies using MD4 × ML5 mice, in which a monoclonal HEL-specific anergic
population exists, suggested that the anergic B cells traffic normally within secondary
lymphoid organs36. However, when anergic B cells coexist with non-anergic B cells (after
adoptive transfer into wild-type mice), their trafficking characteristics were altered. In
studies by Cyster et al.36, it was shown that under conditions of competition anergic B cells
failed to enter the B-cell follicular areas, instead arresting at the T-cell–B-cell boundary in a
process known as follicular exclusion. Recently, Reif et al.51 characterized a mechanism for
the trafficking of B cells within the spleen and lymph nodes. Naive B cells are attracted to
the follicular area by chemotaxis to CXC-chemokine ligand 13 (CXCL13). Following
antigen encounter, these cells upregulate the expression of CC-chemokine receptor 7
(CCR7), which increases their sensitivity to the chemo-kines CCL19 and CCL21 that are
present in the T-cell zone. This promotes B-cell migration to the T-cell areas, allowing
productive T-cell–B-cell collaboration. Perhaps not surprisingly, anergic B cells act as
though they have received BCR signals and accumulate in cortical areas where they search
for help from T cells.
Follicular exclusion has been observed in other anergy models, including VH3H9 mice32
and in dsDNA-specific B cells from Rag–/– VH3H9/Vλ2 mice transferred into wild-type
hosts33. This is in contrast to ssDNA-specific B cells (from VH3H9 × Vκ8 mice)33 and B
cells from Sm-specific (VH2–12) models24, which all enter B-cell follicles effectively. It is
currently unclear where An1 B cells reside in secondary lymphoid tissue, although it would
be interesting to determine their localization.
Effects of innate immune signals
TLRs and their agonists have key roles in innate and adaptive immunity and contribute to
autoimmunity17,52. Two mechanisms are known to modulate the function of self-reactive B
cells during innate immune responses. The first was defined in the MD4 × ML5 model, in
which chronic antigen stimulation reduces plasma-cell generation and antibody secretion
following stimulation of TLR9 (with CpG-containing DNA) and TLR4 (with LPS) in vitro.
The repression of the TLR-mediated antibody secretion response is dependent on MEKs
(mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK)
kinases)9,10. A second mechanism was defined in the Sm-specific model, in which dendritic
cells (DCs) and macrophages selectively repress antibody production by self-reactive B cells
but not naive B cells53. Repression is partly mediated by soluble factors, such as
interleukin-6 (IL-6) and soluble CD40 ligand (CD40L), secreted by activated DCs and
macrophages, and by an ill-defined, contact-dependent mechanism53–55. So, chronic binding
of self antigen may reprogram IL-6 receptor and CD40 signalling, leading to alternative
outcomes in autoreactive B cells. These findings raise the possibility that whereas BCR
signals triggered by high-avidity self antigen are sufficient to silence autoreactive B cells,
BCR signals triggered by low-avidity self antigen may require complementation by
additional or unique mechanisms.
During innate immune responses, naive B cells proliferate and upregulate their expression of
co-stimulatory molecules in response to TLR ligation. By contrast, some autoreactive B
cells proliferate, yet maintain anergy and fail to secrete immunoglobulin in response to TLR
ligation5,13,14,27,41,55 (S.B.G. and J.C.C., unpublished observations). This suggests no
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obligate link between antibody secretion and proliferation. There is a similar relationship
between the upregulation of expression of co-stimulatory molecules and antibody secretion.
LPS upregulates CD86 expression on anergic B cells from HEL-specific56, Ars-specific30
and insulin-specific (VH125 × Vκ125)27 models, despite a lack of antibody secretion.
Interestingly, B cells from the insulin-specific model fail to proliferate in response to LPS,
yet they upregulate CD86 expression27. This suggests that although some TLR4 signal-
transduction pathways remain intact in anergic B cells, others do not.
BCR signalling in B-cell anergy
Antigen-induced aggregation of the BCR on normal mature B cells results in the initiation of
signalling cascades that culminate in proliferation, the upregulation of co-stimulatory
molecules and alterations in gene transcription. By contrast, many anergic B cells are
defective in these responses. Downmodulation of surface IgM on anergic cells was thought
to be partly responsible for diminished downstream signalling responses. However, this
seems unlikely for three reasons. First, HEL- and Ars-specific anergic B cells express
normal, if not higher, levels of surface IgD6,28, resulting in the same overall antigen-binding
capacity between the anergic B cells and naive B cells. Yet antibody-mediated aggregation
of total surface immunoglobulin in both systems does not induce productive downstream
signalling. Second, Ars-specific B cells have only a modest reduction (~30%) in surface
IgM. Third, only a fraction (10%) of the total surface IgM on naive B cells must be
aggregated to induce most responses57,58.
Elucidation of the signalling defects in anergic cells will undoubtedly shed light on the
mechanism(s) by which chronic antigen exposure attenuates signalling by unoccupied
BCRs. Interestingly, defects have been noted in the most receptor-proximal signalling events
following acute antigen stimulation of anergic cells. In anergic B cells from MD4 × ML5
mice, BCR aggregation fails to induce tyrosine phosphorylation of Igα and Igβ or SYK
(spleen tyrosine kinase), despite expression of these proteins at levels comparable to non-
anergic B cells48,59. Similar observations have been made in Ars-specific B cells (K.T.M., J.
M. Dal Porto, S.B.G. and J.C.C., unpublished observations) and dsDNA-specific B cells
(from VH3H9 × Vλ2 mice)33, although the provision of T-cell-derived signals to these
dsDNA-specific B cells in vitro results in the recovery of defective BCR-mediated SYK
phosphorylation. BCR ‘desensitization’ or defective signalling in B cells chronically
exposed to self antigen may occur by ineffective aggregation of surface immunoglobulin,
ineffective association between surface immunoglobulin and its signalling components Igα
and Igβ, or repression of BCR signal transduction by phosphatases (see later).
More distal effects of BCR-mediated signalling are also affected in anergic cells. For
example, HEL-specific B cells from MD4 × ML5 mice fail to mobilize intracellular Ca2+
following BCR aggregation, although these cells have a constitutive increase in basal
intracellular Ca2+ levels (~50 nM) compared with follicular cells48,59,60. Similarly, despite
the increased basal levels of phosphorylated LYN and ERK in HEL-specific B cells, the
phosphorylation of these key signalling molecules is not further increased on stimulation of
the BCR with HEL or IgM-specific antibody60. Ars-specific and An1 B cells show a similar
pattern of elevated basal levels of intracellular Ca2+ and phosphorylation of signalling
effectors, and these effectors are also not upregulated upon stimulation with IgM-specific
antibody28,29 (S.B.G., K.T.M. and J.C.C., unpublished observations).
In some anergic models, B cells respond to BCR aggregation under certain ‘extreme’
circumstances, suggesting that BCR desensitization is not complete. For example, high-
avidity polyclonal IgM-specific antibodies induce robust tyrosine phosphorylation and
intracellular Ca2+ mobilization in insulin-specific B cells (from VH125 × Vκ125 mice). This
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is somewhat paradoxical because in this model, immunization with antigen fails to elicit
antibody production61. This may simply reflect the ability of high-avidity crosslinkers (such
as polyclonal IgM-specific antibody) to overcome tolerance induced by the low-avidity
antigen–BCR inter action. This concept may be relevant to the development of SLE, as
membranes of apoptotic cells contain high levels of nuclear self antigen20,62, which may be
capable of overcoming tolerance induced by a lower-avidity version of the same self
antigen. Alternatively, such high-avidity antigens may overcome ignorance in certain
autoimmune-prone genetic backgrounds. Similarly, co-stimulation of BCRs and TLRs by
apoptotic cells may preclude unresponsiveness63. Thus, multiple mechanisms may
determine the responsiveness of self-reactive B cells during adaptive and innate immune
responses, with variables such as receptor affinity, antigen avidity and antigen availability
all contributing to the overall anergic phenotype.
Biological consequences of BCR signalling in anergic cells
An important aspect of the specific defects in BCR signalling described above is whether
they preclude participation of anergic B cells in immune responses or are epiphenomena. In
normal B cells, BCR aggregation leads to the upregulation of the expression of CD80 and
CD86. This enables B cells to promote T-cell activation, with subsequent B-cell
proliferation and differentiation. However, anergic B cells from MD4 × ML5 and Ars-
specific models fail to upregulate CD86 expression to levels similar to those for non-anergic
B cells28,30,44,56. In addition, CD80 (which is expressed at higher than normal levels on Ars-
specific B cells in the basal state but is not sufficient to drive T-cell activation) is poorly
upregulated by both Ars-specific and HEL-specific B cells following BCR
aggregation28,30,44,56,64. By contrast, BCR-mediated upregulation of CD86 expression is
fully functional in insulin-specific B cells from Vh125×Vκ125 mice27, yet these cells are
unable to mount T-cell-dependent immune responses26. Interestingly, all of these anergic B
cells, including those from HEL-, Ars-, ssDNA-, insulin- and dsDNA-specific models, can
be stimulated by IL-4 and CD40-specific antibody in vitro, suggesting that they are capable
of responding to T-cell-derived signals if they are provided in the correct context27,33,41,65
(S.B.G. and J.C.C., unpublished observations).
The physiological relevance of attenuated CD86 expression after BCR aggregation was
made clear in work by Rathmell et al.43,44,66. Defective upregulation of CD86 expression
promotes FAS-mediated apoptosis of HEL-specific anergic B cells by CD4+ T cells.
Moreover, enforced expression of CD86 in these B cells was sufficient to drive proliferation
and antibody production in the presence of antigen-specific CD4+ T cells. It is therefore
clear that the dysregulation of attenuated CD86 expression by anergic B cells could have
marked consequences for autoimmunity.
In addition to the expression of activation markers, BCR-mediated proliferation is attenuated
in anergic B cells from HEL-specific (MD4 × ML5)5,48, Ars-specific (S.B.G. and J.C.C.,
unpublished observations), dsDNA-specific (VH3H9 × Vλ2)33, ssDNA-specific (VH3H9 ×
Vκ8)14,33 and insulin-specific (VH125×Vκ125)27 models. Whether these models share a
common mechanism for this pheno type is unclear, but it is unlikely. In the MD4 × ML5
model, for example, BCR aggregation fails to induce the phosphorylation and subsequent
degradation of IkB (inhibitor of nuclear factor-κB (NF-κB)), which therefore prevents the
nuclear translocation of NF-κB that is necessary for gene activation and B-cell proliferation.
By contrast, no such defect in IκB degradation is observed in Ars-specific anergic B cells
(S.B.G. and J.C.C., unpublished observations).
In summary, it is clear that chronic exposure of self-reactive B cells to antigen stimulates
intracellular signalling mechanisms that prevent subsequent activation of these cells to
further antigen exposure. However, as is clear for other features of anergic cells, such as
Cambier et al. Page 9













reduced lifespan, these defects are heterogeneous. This heterogeneity is perhaps best
identified in the HEL- and Ars-specific models of anergy, in which similar defects in
proximal BCR signalling are observed (such as defective phosphorylation of Igα, Igβ and
SYK) but distal events are differentially affected (such as IκB degradation).
Mechanisms of signalling defects in anergy
Chronic versus acute signalling
Tenets of specificity dictate that silencing of self-reactive B cells by anergy must be initiated
by the binding of self antigen. B cells cannot distinguish between self and non-self antigens,
therefore the decision to become anergic must be based on whether secondary signals are
received within a specific time frame. It is not surprising, therefore, that an anergic state can
be induced simply by treating isolated B cells with either antigen or immunoglobulin-
specific antibodies for a prolonged period of time. The consequence of this receptor
desensitization is a constitutive increase in the levels of intracellular free Ca2+ and tyrosine
phosphorylation similar to that seen in anergic B cells from the MD4 × ML5 and Ars-
specific models57,58. Two observations confirm the requirement of prolonged or constant
signalling for anergy or BCR desensitization. First, anergic HEL-specific B cells that are
transferred into recipients devoid of HEL regain the ability to mature (progressing past the
T3 B-cell developmental stage29) and to mount an antibody response5. Second, many
biochemical features of anergic B cells are reversed following withdrawal of the self-antigen
signal30,53. Both these lines of evidence suggest that chronic signalling in the absence of
secondary signals (by T cells, for example) is central to the maintenance of anergy.
Biased activation of inhibitory signalling circuitry in anergic cells
As described above, chronic exposure to self antigen increases basal levels of
phosphorylation of proteins such as LYN. But how does this translate into attenuated BCR-
mediated signalling upon restimulation? It is possible that LYN mediates an effect by
phosphorylating the inhibitory co-receptor CD22 and by recruiting the phosphatase SHP1
(SH2-domain-containing protein tyrosine phosphatase 1) to the BCR complex67. However,
this has not been demonstrated in most anergy models. This notwithstanding, Cd22–/–
animals are known to produce autoantibodies spontaneously68. In addition, mice lacking
LYN or expressing constitutively active LYN develop autoimmunity69, confirming a key
role for LYN in B-cell anergy.
LYN has also been shown to be important in the phosphorylation and activation of the
phosphatase SHIP1 (SH2-domain-containing inositol polyphosphate 5′ phosphatase 1) and
its adaptor DOK (docking protein). These molecules form a bidentate inhibitory complex
following co-aggregation of the BCR with the inhibitory Fc receptor for IgG, FcγRIIb. We
have recently shown that SHIP1 and DOK1 are also hyperphosphorylated in anergic B cells
from the HEL- and Ars-specific models and in An1 B cells from normal mice29 (K.T.M. and
J.C.C., unpublished observations). Thus, chronic BCR signalling also activates this circuit.
In addition, when crossed onto a SHIP1-deficient background, anergy is lost in both the Ars-
and HEL-specific models, as well as in wild-type animals. Studies in our laboratory indicate
that activation of SHIP1 and DOK1 in anergic cells results from biased monophosphory
lation of tyrosine residues in the ITAMs (immunoreceptor tyrosine-based activation motifs)
of Igα and Igβ (FIG. 2). Dual ITAM tyrosine phosphorylation occurs in the initial B-cell
response to antigen, and is required for the recruitment of SYK and for the induction of
productive downstream signalling. In anergic cells, however, ITAMs are constitutively
monophosphorylated. Studies of signalling by chimeric receptors in a mouse B-cell line
have confirmed that monophosphorylation of the Igα and Igβ ITAMs leads to activation of
the SHIP1–DOK pathway70 (K.T.M. and J.C.C., unpublished observations).
Cambier et al. Page 10













Another signalling molecule that is thought to have a role in the induction of anergy is
protein kinase Cδ (PKCδ). The absence of this protein has previously been shown to result
in the loss of anergy and the development of autoimmunity71,72. This may be linked to the
proposed role for nuclear translocation of PKCδ in the induction of B-cell apoptosis73.
Interestingly, it has been shown that BAFF prevents this translocation and hence prevents B-
cell death. Given the autoimmune phenotype of mice that overexpress BAFF74 and the lack
of B-cell anergy in PKCδ-deficient animals, a key role for BAFF in regulating the survival
of anergic B cells is likely.
It is worth noting that the use of knockout mice to determine the importance of various
proteins in tolerance induction can be subject to misinterpretation. As previously mentioned,
it is reported that T-cell signals only break or prevent tolerance in B cells that are recently
exposed to self antigen. By extension, it is reasonable to suggest that such genetic
manipulations may have effects that occur before the induction of anergy, rather than
breaking anergy per se. A further confounding effect in such circumstances is the production
of antibodies that neutralize the self antigen, contributing to the illusion that anergy is
broken. The generation of anergic mouse models crossed with conditional knockout mice, in
which the deletion of a specific gene can be induced in a specific cell population (one that is
already anergic, for example), should help to resolve this problem.
Trans-effects of chronic BCR signalling
The ability of signalling molecules to act in trans between different receptors is well known.
In the case of B-cell anergy, inhibitory signals generated by chronic BCR stimulation act in
trans on chemokine receptors. Work by Brauweiler et al.75 has shown that migration in
response to CXCL12 is inhibited in anergic B cells from Ars- and HEL-specific models and
in in vitro antigen-stimulated B cells. Interestingly, this is known to be a SHIP1-dependent
mechanism, which suggests that activated SHIP1 induced by prolonged exposure to self
antigen might act in trans to inhibit signalling by other receptors that have a functional
requirement for phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) for function. It
will be interesting to examine whether other receptors expressed on B cells, which are
known to use PtdIns(3,4,5)P3, are similarly affected. One possible candidate is the receptor
for BAFF, which is known to signal through phosphoinositide 3-kinase, as anergic B cells
might have a decreased capacity to respond to BAFF39,76.
Concluding remarks
It is clear that B-cell anergy is a key physiological mechanism for silencing self-reactive B
cells and thereby preventing autoimmunity. However, it is also clear that anergy is complex,
plastic and mechanistically diverse. This might be expected based on the fact that anergy
must mediate silencing of B cells that bind self antigens of diverse valency and affinity. In
some anergic B cells, proximal BCR signalling events appear to be intact. However, other
anergic B cells are unresponsive to both BCR and TLR stimulation. Consistent among all
models, however, is the inability of anergic B cells to respond to antigen by secreting
immunoglobulin. Ultimately however, the goal of preventing autoimmunity is achieved. The
recent discovery of An1 B cells in wild-type animals will undoubtedly open new avenues for
study in this field. They provide the opportunity to study a cross-section of anergic B cells
that develop in a physiological setting.
Perhaps the greatest challenge facing this field is understanding how reversibility, BCR
affinity and self-antigen avidity are accommodated in silencing anergic B cells. It is easy to
understand how high-avidity interactions of a BCR with self antigen, and the potent signals
they induce, would lead to irreversible silencing by BCR editing or deletion. However,
dealing with self-antigen avidities ranging from those that barely exceed the threshold for
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ignorance to those that approach the threshold for editing is a daunting problem, especially
when one considers that the avidity of the anergy-inducing ligand may be quite different
from that of a mimicking antigen presented by a pathogen that threatens to break tolerance.
Although the decision to edit is analogous to a switch, anergy requires an almost infinitely
variable rheostat. Although not formally proven, it is probably safe to assume that the
differences observed in the features of anergic B cells from the models discussed can, in
large part, be accounted for by differences in antigen avidity.
The situation becomes particularly challenging at the low-avidity end of the spectrum. At
what point does anergy give way to ignorance? Although B cells in all the models described
in this Review seem to be anergic at the level of attenuated in vivo immune responses, some
appear to be more anergic than others with respect to signalling and early biological
responses. In other models, such as the AM14 rheumatoid-factor mouse, B cells seem to be
truly ignorant despite being exposed to moderate-affinity, albeit monovalent, antigen. On
autoimmune-prone backgrounds, AM14 B cells make autoantibodies77,78. Understanding
the mechanisms that lead to B-cell silencing in vivo, regardless of whether the self antigen is
DNA or myelin, is essential in our quest to understand autoimmunity and develop new
strategies for the treatment and management of these diseases.
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Glossary
Receptor editing A molecular process that involves secondary rearrangements
(mostly of the light chains) that replace existing
immunoglobulin molecules and generate a new antigen receptor
with altered specificity.
Central tolerance Self-tolerance that is created at the level of the central lymphoid
organs. Developing T cells in the thymus and B cells in the
bone marrow, that strongly recognize self antigen face deletion
or marked suppression.
Anergy A state of non-responsiveness to antigen. Anergic T or B cells




(SLE). An autoimmune disease in which autoantibodies
specific for DNA RNA or proteins associated with nucleic
acids form immune complexes. These complexes damage small
blood vessels, especially in the kidneys. Patients with SLE
generally have abnormal B- and T-cell function.
MRL.Faslpr/lpr mice A mouse strain that spontaneously develops glomerulonephritis
and other symptoms of systemic lupus erythematosus. The lpr
mutation causes a defect in FAS (also known as CD95)
preventing the apoptosis of activated lymphocytes the MRL




(snRNP). A nuclear particle that consists of a short RNA (<300
nucleotides) and one or more tightly bound proteins. They are
involved in pre-mRNA processing and tRNA biogenesis.
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(NOD mice). A strain of mice that normally develop idiopathic
autoimmune diabetes that closely resembles type 1 diabetes in
humans. The main component of susceptibility is the unique
MHC haplotype H2g7.
References
1. Wardemann H, et al. Predominant autoantibody production by early human B cell precursors.
Science. 2003; 301:1374–1377. [PubMed: 12920303] This paper shows that a high frequency of
early immature B cells generated during human B-cell development are self-reactive.
2. Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to
escape tolerance. J. Exp. Med. 1993; 177:999–1008. [PubMed: 8459227]
3. Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J. Exp.
Med. 1993; 177:1009–1020. [PubMed: 8459201]
4. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC
class I antibody genes. Nature. 1989; 337:562–566. [PubMed: 2783762]
5. Goodnow CC, Brink R, Adams E. Breakdown of self-tolerance in anergic B lymphocytes. Nature.
1991; 352:532–536. [PubMed: 1830923]
6. Goodnow CC, et al. Altered immunoglobulin expression and functional silencing of self-reactive B
lymphocytes in transgenic mice. Nature. 1988; 334:676–682. [PubMed: 3261841] This work
identifies key phenotypic features of anergic cells in the classic HEL-specific B-cell model.
7. Goodnow CC, Crosbie J, Jorgensen H, Brink RA, Basten A. Induction of self-tolerance in mature
peripheral B lymphocytes. Nature. 1989; 342:385–391. [PubMed: 2586609]
8. Goodnow CC, et al. Clonal silencing of self-reactive B lymphocytes in a transgenic mouse model.
Cold Spring Harb. Symp. Quant. Biol. 1989; 54:907–920. [PubMed: 2701221]
9. Rui L, Vinuesa CG, Blasioli J, Goodnow CC. Resistance to CpG DNA-induced autoimmunity
through tolerogenic B cell antigen receptor ERK signaling. Nature Immunol. 2003; 4:594–600.
[PubMed: 12740574]
10. Rui L, Healy JI, Blasioli J, Goodnow CC. ERK signaling is a molecular switch integrating
opposing inputs from B cell receptor and T cell cytokines to control TLR4-driven plasma cell
differentiation. J. Immunol. 2006; 177:5337–5346. [PubMed: 17015719]
11. Shlomchik MJ, Aucoin AH, Pisetsky DS, Weigert MG. Structure and function of anti-DNA
autoantibodies derived from a single autoimmune mouse. Proc. Natl Acad. Sci. USA. 1987;
84:9150–9154. [PubMed: 3480535]
12. Erikson J, et al. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice.
Nature. 1991; 349:331–334. [PubMed: 1898987]
13. Roark JH, Bui A, Nguyen KA, Mandik L, Erikson J. Persistence of functionally compromised anti-
double-stranded DNA B cells in the periphery of non-autoimmune mice. Int. Immunol. 1997;
9:1615–1626. [PubMed: 9418123]
14. Nguyen KA, et al. Characterization of anti-single-stranded DNA B cells in a non-autoimmune
background. J. Immunol. 1997; 159:2633–2644. [PubMed: 9300682]
15. Mandik-Nayak L. MRL-lpr/lpr mice exhibit a defect in maintaining developmental arrest and
follicular exclusion of anti-double-stranded DNA B cells. J. Exp. Med. 1999; 189:1799–1814.
[PubMed: 10359584]
16. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell
biology. Adv. Immunol. 1989; 44:93–151. [PubMed: 2646863]
17. Lau CM, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/
Toll-like receptor 7 engagement. J. Exp. Med. 2005; 202:1171–1177. [PubMed: 16260486]
18. Bloom DD, Davignon JL, Cohen PL, Eisenberg RA, Clarke SH. Overlap of the anti-Sm and anti-
DNA responses of MRL/Mp-lpr/lpr mice. J. Immunol. 1993; 150:1579–1590. [PubMed: 8432994]
Cambier et al. Page 13













19. Qian Y, et al. Autoreactive MZ and B-1 B-cell activation by Faslpr is coincident with an increased
frequency of apoptotic lymphocytes and a defect in macrophage clearance. Blood. 2006; 108:974–
982. [PubMed: 16861350]
20. Qian Y, Wang H, Clarke SH. Impaired clearance of apoptotic cells induces the activation of
autoreactive anti-Sm marginal zone and B-1 B cells. J. Immunol. 2004; 172:625–635. [PubMed:
14688375]
21. Culton DA, et al. Early preplasma cells define a tolerance checkpoint for autoreactive B cells. J.
Immunol. 2006; 176:790–802. [PubMed: 16393962]
22. Santulli-Marotto S, Retter MW, Gee R, Mamula MJ, Clarke SH. Autoreactive B cell regulation:
peripheral induction of developmental arrest by lupus-associated autoantigens. Immunity. 1998;
8:209–219. [PubMed: 9492002]
23. Retter MW, Eisenberg RA, Cohen PL, Clarke SH. Sm and DNA binding by dual reactive B cells
requires distinct VH, Vκ, and VH CDR3 structures. J. Immunol. 1995; 155:2248–2257. [PubMed:
7636271]
24. Borrero M, Clarke SH. Low-affinity anti-Smith antigen B cells are regulated by anergy as opposed
to developmental arrest or differentiation to B-1. J. Immunol. 2002; 168:13–21. [PubMed:
11751941]
25. Ewulonu UK, Nell LJ, Thomas JW. VH, VL gene usage by murine IgG antibodies that bind
autologous insulin. J. Immunol. 1990; 144:3091–3098. [PubMed: 2109009]
26. Rojas M, Hulbert C, Thomas JW. Anergy and not clonal ignorance determines the fate of B cells
that recognize a physiological autoantigen. J. Immunol. 2001; 166:3194–3200. [PubMed:
11207272]
27. Acevedo-Suarez CA, Hulbert C, Woodward EJ, Thomas JW. Uncoupling of anergy from
developmental arrest in anti-insulin B cells supports the development of autoimmune diabetes. J.
Immunol. 2005; 174:827–833. [PubMed: 15634904]
28. Benschop RJ, et al. Activation and anergy in bone marrow B cells of a novel immunoglobulin
transgenic mouse that is both hapten specific and autoreactive. Immunity. 2001; 14:33–43.
[PubMed: 11163228]
29. Merrell KT, et al. Identification of anergic B cells within a wild-type repertoire. Immunity. 2006;
25:953–962. [PubMed: 17174121]
30. Gauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy requires constant
antigen receptor occupancy and signaling. Nature Immunol. 2005; 6:1160–1167. [PubMed:
16200069] This paper suggests that anergy is a rapidly reversible phenotype that is dependent on
constant self-antigen binding to the antigen receptor.
31. Teague BN, et al. Cutting Edge: Transitional t3 B cells do not give rise to mature B cells, have
undergone selection, and are reduced in murine lupus. J. Immunol. 2007; 178:7511–7515.
[PubMed: 17548583]
32. Mandik-Nayak L, Bui A, Noorchashm H, Eaton A, Erikson J. Regulation of anti-double-stranded
DNA B cells in nonautoimmune mice: localization to the T–B interface of the splenic follicle. J.
Exp. Med. 1997; 186:1257–1267. [PubMed: 9334365]
33. Noorchashm H, et al. Characterization of anergic anti-DNA B cells: B cell anergy is a T cell-
independent and potentially reversible process. Int. Immunol. 1999; 11:765–776. [PubMed:
10330282]
34. Fulcher DA, Basten A. Reduced life span of anergic self-reactive B cells in a double-transgenic
model. J. Exp. Med. 1994; 179:125–134. [PubMed: 8270860] This paper is one of several key
studies that identify the short half-life of self-reactive B cells.
35. Tough DF, Sprent J. Lifespan of lymphocytes. Immunol. Res. 1995; 14:1–12. [PubMed: 7561338]
36. Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-reactive cells
from the recirculating B-cell repertoire. Nature. 1994; 371:389–395. [PubMed: 7522305] This
work shows that competition of anergic B cells within a normal B-cell repertoire contributes to
their short lifespan.
37. Cyster JG, Goodnow CC. Antigen-induced exclusion from follicles and anergy are separate and
complementary processes that influence peripheral B cell fate. Immunity. 1995; 3:691–701.
Cambier et al. Page 14













[PubMed: 8777715] This paper highlights the exclusion of self-reactive B cells from follicular
areas and shows their localization to the T-cell–B-cell interface.
38. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival.
Annu. Rev. Immunol. 2003; 21:231–264. [PubMed: 12427767]
39. Lesley R, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased
dependence on BAFF. Immunity. 2004; 20:441–453. [PubMed: 15084273] This paper shows the
reduced capacity of self-reactive B cells to compete for the B-cell survival signal BAFF, thereby
contributing to their short lifespan.
40. Oliver PM, Vass T, Kappler J, Marrack P. Loss of the proapoptotic protein, Bim, breaks B cell
anergy. J. Exp. Med. 2006; 203:731–741. [PubMed: 16520387]
41. Mandik-Nayak L, et al. Functional consequences of the developmental arrest and follicular
exclusion of anti-double-stranded DNA B cells. J. Immunol. 2000; 164:1161–1168. [PubMed:
10640726]
42. Weintraub JP, et al. Immunological and pathological consequences of mutations in both Fas and
Fas ligand. Cell. Immunol. 1998; 186:8–17. [PubMed: 9637760]
43. Rathmell JC, et al. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with
CD4+ T cells. Nature. 1995; 376:181–184. [PubMed: 7603571]
44. Rathmell JC, Fournier S, Weintraub BC, Allison JP, Goodnow CC. Repression of B7.2 on self-
reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4+ T
cells. J. Exp. Med. 1998; 188:651–659. [PubMed: 9705947]
45. Feuerstein N, Chen F, Madaio M, Maldonado M, Eisenberg RA. Induction of autoimmunity in a
transgenic model of B cell receptor peripheral tolerance: changes in coreceptors and B cell
receptor-induced tyrosine-phosphoproteins. J. Immunol. 1999; 163:5287–5297. [PubMed:
10553051]
46. Sekiguchi DR, et al. Chronic graft-versus-host in Ig knockin transgenic mice abrogates B cell
tolerance in anti-double-stranded DNA B cells. J. Immunol. 2002; 168:4142–4153. [PubMed:
11937575]
47. Seo SJ, et al. The impact of T helper and T regulatory cells on the regulation of anti-double-
stranded DNA B cells. Immunity. 2002; 16:535–546. [PubMed: 11970877]
48. Cooke MP, et al. Immunoglobulin signal transduction guides the specificity of B cell–T cell
interactions and is blocked in tolerant self-reactive B cells. J. Exp. Med. 1994; 179:425–438.
[PubMed: 8294858]
49. Foote LC, Marshak-Rothstein A, Rothstein TL. Tolerant B lymphocytes acquire resistance to Fas-
mediated apoptosis after treatment with interleukin 4 but not after treatment with specific antigen
unless a surface immunoglobulin threshold is exceeded. J. Exp. Med. 1998; 187:847–853.
[PubMed: 9500787]
50. Cook MC, Basten A, Fazekas de St Groth B. Rescue of self-reactive B cells by provision of T cell
help in vivo . Eur. J. Immunol. 1998; 28:2549–2558. [PubMed: 9710232]
51. Reif K, et al. Balanced responsiveness to chemoattractants from adjacent zones determines B-cell
position. Nature. 2002; 416:94–99. [PubMed: 11882900]
52. Pisitkun P, et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene
duplication. Science. 2006; 312:1669–1672. [PubMed: 16709748]
53. Kilmon MA, Rutan JA, Clarke SH, Vilen BJ. Low-affinity, Smith antigen-specific B cells are
tolerized by dendritic cells and macrophages. J. Immunol. 2005; 175:37–41. [PubMed: 15972629]
54. Gilbert MR, et al. Dendritic cells from lupus-prone mice are defective in repressing
immunoglobulin secretion. J. Immunol. 2007; 178:4803–4810. [PubMed: 17404261]
55. Kilmon MA, et al. Macrophages prevent the differentiation of autoreactive B cells by secreting
CD40 ligand and IL-6. Blood. in the press.
56. Lenschow DJ, et al. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after
Ig receptor engagement by antigen. J. Immunol. 1994; 153:1990–1997. [PubMed: 7519638]
57. Vilen BJ, Famiglietti SJ, Carbone AM, Kay BK, Cambier JC. B cell antigen receptor
desensitization: disruption of receptor coupling to tyrosine kinase activation. J. Immunol. 1997;
159:231–243. [PubMed: 9200459]
Cambier et al. Page 15













58. Vilen BJ, Burke KM, Sleater M, Cambier JC. Transmodulation of BCR signaling by transduction-
incompetent antigen receptors: implications for impaired signaling in anergic B cells. J. Immunol.
2002; 168:4344–4351. [PubMed: 11970976]
59. Weintraub BC, et al. Entry of B cell receptor into signaling domains is inhibited in tolerant B cells.
J. Exp. Med. 2000; 191:1443–1448. [PubMed: 10770810] This paper highlights defective B-cell
signalling by anergic B cells.
60. Healy JI, et al. Different nuclear signals are activated by the B cell receptor during positive versus
negative signaling. Immunity. 1997; 6:419–428. [PubMed: 9133421] This work highlights key
signalling phenotypes of self-reactive B cells.
61. Acevedo-Suarez CA, Kilkenny DM, Reich MB, Thomas JW. Impaired intracellular calcium
mobilization and NFATc1 availability in tolerant anti-insulin B cells. J. Immunol. 2006;
177:2234–2241. [PubMed: 16887983]
62. Radic M, Marion T, Monestier M. Nucleosomes are exposed at the cell surface in apoptosis. J.
Immunol. 2004; 172:6692–6700. [PubMed: 15153485]
63. Leadbetter EA, et al. Chromatin–IgG complexes activate B cells by dual engagement of IgM and
Toll-like receptors. Nature. 2002; 416:603–607. [PubMed: 11948342]
64. Ho WY, Cooke MP, Goodnow CC, Davis MM. Resting and anergic B cells are defective in CD28-
dependent costimulation of naive CD4+ T cells. J. Exp. Med. 1994; 179:1539–1549. [PubMed:
7909325]
65. Eris JM, et al. Anergic self-reactive B cells present self antigen and respond normally to CD40-
dependent T-cell signals but are defective in antigen-receptor-mediated functions. Proc. Natl Acad.
Sci. USA. 1994; 91:4392–4396. [PubMed: 7514304]
66. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC. Expansion or elimination of B cells
in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor.
Cell. 1996; 87:319–329. [PubMed: 8861915]
67. Smith KG, Tarlinton DM, Doody GM, Hibbs ML, Fearon DT. Inhibition of the B cell by CD22: a
requirement for Lyn. J. Exp. Med. 1998; 187:807–811. [PubMed: 9480991]
68. O’Keefe TL, Williams GT, Batista FD, Neuberger MS. Deficiency in CD22, a B cell-specific
inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J.
Exp. Med. 1999; 189:1307–1313. [PubMed: 10209047]
69. Hibbs ML, et al. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J. Exp.
Med. 2002; 196:1593–1604. [PubMed: 12486102]
70. Pao LI, Famiglietti SJ, Cambier JC. Asymmetrical phosphorylation and function of
immunoreceptor tyrosine-based activation motif tyrosines in B cell antigen receptor signal
transduction. J. Immunol. 1998; 160:3305–3314. [PubMed: 9531288]
71. Miyamoto A, et al. Increased proliferation of B cells and auto-immunity in mice lacking protein
kinase Cδ. Nature. 2002; 416:865–859. [PubMed: 11976687]
72. Mecklenbrauker I, Saijo K, Zheng NY, Leitges M, Tarakhovsky A. Protein kinase Cδ controls self-
antigen-induced B-cell tolerance. Nature. 2002; 416:860–865. [PubMed: 11976686]
73. Mecklenbrauker I, Kalled SL, Leitges M, Mackay F, Tarakhovsky A. Regulation of B-cell survival
by BAFF-dependent PKCδ-mediated nuclear signalling. Nature. 2004; 431:456–461. [PubMed:
15361883]
74. Mackay F, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune
manifestations. J. Exp. Med. 1999; 190:1697–1710. [PubMed: 10587360]
75. Brauweiler A, Merrell K, Gauld SB, Cambier JC. Cutting Edge: Acute and chronic exposure of
immature B cells to antigen leads to impaired homing and SHIP1-dependent reduction in stromal
cell-derived factor-1 responsiveness. J. Immunol. 2007; 178:3353–3357. [PubMed: 17339427]
76. Thien M, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows
them to enter forbidden follicular and marginal zone niches. Immunity. 2004; 20:785–798.
[PubMed: 15189742]
77. Shlomchik MJ, Euler CW, Christensen SC, William J. Activation of rheumatoid factor (RF) B cells
and somatic hypermutation outside of germinal centers in autoimmune-prone MRL/ lpr mice. Ann.
N.Y. Acad. Sci. 2003; 987:38–50. [PubMed: 12727622]
Cambier et al. Page 16













78. Wang H, Shlomchik MJ. Autoantigen-specific B cell activation in Fas-deficient rheumatoid factor
immunoglobulin transgenic mice. J. Exp. Med. 1999; 190:639–649. [PubMed: 10477549]
79. Pugh-Bernard AE, et al. Regulation of inherently autoreactive VH4–34 B cells in the maintenance
of human B cell tolerance. J. Clin. Invest. 2001; 108:1061–1070. [PubMed: 11581307]
80. Stevenson FK, Smith GJ, North J, Hamblin TJ, Glennie MJ. Identification of normal B-cell
counterparts of neoplastic cells which secrete cold agglutinins of anti-I and anti-i specificity. Br. J.
Haematol. 1989; 72:9–15. [PubMed: 2472169]
81. Isenberg DA, et al. Correlation of 9G4 idiotope with disease activity in patients with systemic
lupus erythematosus. Ann. Rheum. Dis. 1998; 57:566–570. [PubMed: 9849317]
82. van Vollenhoven RF, et al. VH4–34 encoded antibodies in systemic lupus erythematosus: a
specific diagnostic marker that correlates with clinical disease characteristics. J. Rheumatol. 1999;
26:1727–1733. [PubMed: 10451069]
83. Allman D, et al. Resolution of three nonproliferative immature splenic B cell subsets reveals
multiple selection points during peripheral B cell maturation. J. Immunol. 2001; 167:6834–6840.
[PubMed: 11739500]
Cambier et al. Page 17













Box 1 | Anergy in humans
Although humans1 and mice both produce self-reactive B cells at high frequency in the
bone marrow, only in mice has a self-reactive anergic B-cell population been identified in
the periphery. Therefore, it has not been possible to study the role that anergy has in
preventing human autoimmune disease, nor to compare the signalling and phenotypic
characteristics of human versus mouse anergic B cells. Studies have found that human B
cells using the immunoglobulin heavy chain gene VH4–34 are inheritably self-reactive,
independent of immunoglobulin light-chain usage79. Indeed, serum levels of VH 4–34-
containing antibodies account for approximately 0.5% of total immunoglobulin in
healthy humans80. In patients with systemic lupus erythematosus, the levels of these
antibodies are increased and correlate with disease81,82. However, it is unclear whether
these B cells, which are good candidates for a human anergic B-cell population, also
express novel cell-surface markers that can be used to isolate these cells from human
tissue. Such information, as we now have for a population in mice, would allow us to
monitor the entrance and departure of autoreactive clonotypes from the anergic
compartment and thus begin to understand the forces that drive autoimmunity in humans.
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Figure 1. Stages of B-cell development
B-cell development occurs in both the bone marrow and peripheral lymphoid tissues such as
the spleen. In the bone marrow, development progresses through the pro-B-cell, pre-B-cell
and immature-B-cell stages. During this differentiation, rearrangements at the
immunoglobulin locus result in the generation and surface expression of the pre-B-cell
receptor (pre-BCR, which is comprised of an Igµ heavy chain and surrogate light chains
(VpreB or Vλ5)) and finally a mature BCR (comprised of rearranged heavy- and light-chain
genes) that is capable of binding antigen. At this immature stage of development, B cells
undergo a selection process to prevent any further development of self-reactive cells. Both
receptor editing and clonal deletion have a role at this stage. Cells successfully completing
this checkpoint leave the bone marrow as transitional B cells, eventually maturing into
mature follicular B cells (or marginal-zone B cells). Following an immune response,
antigen-specific B cells develop into either plasma (antibody-secreting) cells or memory B
cells. Transitional 3 (T3) B cells, once thought to be part of the linear development from
immature to mature B cells, are now thought to represent primarily self-reactive anergic B
cells (also known as An1 B cells).
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Figure 2. B-cell signalling in response to acute or chronic antigen stimulation
a | The normal B-cell receptor (BCR) response to acute antigen stimulation involves the
phosphorylation of two tyrosine residues in the ITAMs (immunoreceptor tyrosine-based
activation motifs) of Igα and Igβ by LYN or other SRC-family kinases. This results in the
recruitment and activation of SYK (spleen tyrosine kinase), which in turn phosphorylates
key downstream substrates such as BLNK (B-cell linker) and BTK (Bruton’s tyrosine
kinase), resulting in productive BCR signalling, activation and productive interactions with
helper T cells. b | In anergic B cells, chronic binding of self antigen is thought to favour
monophosphorylation of ITAM tyrosines. This limits the recruitment and activation of SYK,
yet allows efficient LYN activity, which enhances the phosphorylation and activation of an
inhibitory complex containing SHIP1 (SRC-homology-2-domain-containing inositol-5-
phosphatase 1) and DOK (docking protein). These proteins act to dampen any productive
BCR-mediated signalling in a manner that is analogous to FcγRIIb (an inhibitory Fc
receptor for IgG that is expressed by B cells). This inhibitory complex may also act in trans
to inhibit signalling by other receptors, including CXC-chemokine receptor 4 (CXCR4) and
possibly the receptor for B-cell-activating factor (BAFFR). DAG, diacylglycerol; ERK,
extracellular-signal-regulated kinase; GRB2, growth-factor-receptor-bound protein 2; InsP3,
inositol-1,4,5-trisphosphate; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C;
PLCγ, phospholipase Cγ; PtdIns(3,4,5)P3, phosphatidylinositol-3,4,5-trisphosphate;
PtdIns(4,5)P2, phosphatidylinositol-4,5-bisphosphate; SOS, son-of-sevenless homologue.
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